Liquid Biopsy Market Development And Business Growth

Oct. 19, 2021 4:53 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Contributor Since 2014

#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology

Market growth influenced due to following factors-

  • Initiatives undertaken by government and global health organizations.
  • Increasing preference for non-invasive procedures, technological advancement to augment market revenues.
  • Rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.

Global market size-

According to the new market research Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022, at a CAGR of 23.4%.

Leading Players-

The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (OTCPK:ITALY), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).

Top Market Segments-

On the basis of product, the liquid biopsy market is broadly segmented into assays kits, instruments, and services. In 2017, the assay kits segment is expected to account for the largest share of this market.

Based on clinical application, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The therapy selection segment is expected to account for the largest share of the liquid biopsy devices market in 2017. This is due to the ability of therapy selection to detect advanced-stage cancers (stage III and IV), followed by increasing studies on liquid biopsy and advancements made in this field to also aid in detection of early-stage cancers.

For Details, Download PDF Brochure

Geographic Overview -

North America is expected to account for the largest share of the global liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.